No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
www.evotec.comNo one on the platform currently holds EVT.DE.
No tracked institution reports a position in EVT.DE as of their last filing.
No one on the platform has traded EVT.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -1.1% | 9.5% | ||||
| Profit Margin % | -13.1% | -7.4% | 2.1% | |||
| Free Cash Flow Margin % | -10.4% | -8.9% | 1.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $603M | -23.6% | $-1.30 | $-1.57–$-1.03 | — | 2 |
| 2027 | $720M | +19.5% | $-0.32 | $-0.58–$-0.22 | — | 5 |
| 2028 | $782M | +8.6% | $0.02 | $-0.45–$0.43 | — | 5 |
| 2029 | $815M | +4.2% | $0.19 | $0.17–$0.24 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.07 | $-0.26 | -271.4% |
| 2026-05-06 | $-0.24 | $-0.69 | -181.6% |
| 2026-04-08 | $0.31 | $0.08 | -74.2% |
| 2025-11-05 | $-0.13 | $-0.24 | -83.0% |
| 2025-08-13 | $-0.13 | $-0.24 | -93.3% |
| 2025-05-06 | $-0.08 | $-0.18 | -122.3% |
| 2025-04-17 | $0.03 | $-0.23 | -867.8% |
| 2024-11-06 | $-0.11 |
| $-0.22 |
| -100.0% |
| $880M |
| — |
| DRW3.DEDrägerwerk AG & Co. KGaA | $113.00 | +0.53% | $2.1B | — |
| DRW8.DEDrägerwerk AG & Co. KGaA | $85.00 | -1.39% | $2.1B | — |
Source: Financial Modeling Prep · peers by sector/industry